Pfizer Inc on Tuesday said the final analysis of its antiviral COVID-19 lozenge still showed near 90 percent efficacity in precluding hospitalizations and deaths in high- threat cases. Recent lab data suggests the medicine retains its effectiveness against the fast- spreading Omicron variant of the coronavirus The US drugmaker last…